MetabolismNews.net

Metabolism Xagena

Search results for "Forteo"

Researchers at the Stanford University School of Medicine have found that a new osteoporosis drug, called Teriparatide ( Forteo ), is not cost-effective compared with the most commonly prescribed oste ...


Researchers found patients with glucocorticoid-induced osteoporosis who were treated with Teriparatide ( Forteo, Forsteo ) for 36 months had a greater increase in bone mineral density ( BMD ) and fewe ...


New data have shown that Forteo ( Teriparatide; Forsteo ) significantly increased lumbar spine volumetric bone mineral density ( vBMD ) compared to Risedronate ( Actonel ) in men with glucocorticoid-i ...


The results from a phase 2 trial evaluating Romosozumab in postmenopausal women with low bone mineral density ( BMD ) were published in the New England Journal of Medicine ( NEJM ).The trial demonstra ...


Osteoporosis medications increase bone-mineral density ( BMD ) and lower but do not eliminate fracture risk. The combining of anabolic agents with bisphosphonates has not improved efficacy.Researchers ...


Current osteoporosis medications increase bone mineral density ( BMD ) modestly and reduce, but do not eliminate, fracture risk. Attempts to improve efficacy by administering anabolic agents and bisph ...